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ao the Editor: In recent years, the pioneering work of Wijffels et
l. (1) has demonstrated the importance of atrial remodeling in
evelopment of an atrial substrate conducive to sustained atrial
brillation (AF). A range of factors has been implicated in this
rocess. Among these factors, indirect evidence suggests a role for
he renin-angiotensin system. In differing animal models,
ngiotensin-converting enzyme inhibition or angiotensin II (AII)
ntagonists has been shown to prevent both acute (hours) (2)
lectrical remodeling and chronic (weeks) structural remodeling
3). Although the mechanism for these effects remains uncertain,
he inhibition of acute AF-induced remodeling by these agents
uggests that AII may have direct effects on atrial electrophysiol-
gy. In the current study, we examined the acute effects of AII on
trial electrophysiology in humans.
Our study population included 12 patients with supraventricular
achycardia who were undergoing curative ablation. Autonomic
lockade was administered at commencement. Continuous heart
ate and blood pressure monitoring was performed. Multipolar
atheters included: 1) a coronary sinus (CS) catheter; 2) a crista
erminalis (CT) catheter; 3) a lateral right atrium (RA) catheter;
nd 4) a His bundle catheter.
Atrial effective refractory period (ERP) was measured at the
istal CS and high lateral RA at cycle lengths of 600, 500, and 400
s. Dispersion of atrial ERP was defined as the difference between
he averaged atrial ERP at both sites. Atrial conduction was
easured in both atria at pacing cycle lengths of 600, 500, and 400
s. Local conduction time was measured along the lateral RA and
S catheters.
Conduction delay was analyzed by the presence of discrete
ouble potentials and fractionated electrograms and assessed dur-
ng pacing at 600, 500, and 400 ms and during extra stimulus
esting from distal CS and high lateral RA. The inducibility of AF
5 s) was recorded during ERP testing.
Angiotensin II was obtained from Clinalfa AG (Laufelfingen,igure 1. The angiotensin II (An 2) infusion resulted in a significant elevati
p  0.01) and diastolic BP (p  0.01) (right panel) without alteration in heawitzerland). The pure peptide was then dissolved in normal saline
efore infusion. Electrophysiology measurements were performed
t three different AII time points: 1) baseline, 2) low-dose infusion
2 ng/kg/min), and 3) high-dose infusion (5 ng/kg/min). These
oses were chosen as those that have previously resulted in a
ignificant vasopressor effect (4). The AII levels were measured at
hese time points and at 10 min after the AII infusion.
Data are expressed as mean  SEM. For multiple comparisons
etween groups, data were analyzed by repeated-measures analysis
f variance followed by the Scheffé test for multiple comparisons.
tatistical significance was assumed at p  0.05.
Twelve patients (8 female/4 male, mean age 37.7  4.2 years)
nderwent an electrophysiology study. Plasma AII levels were 57.0
14.8 pg/ml at baseline, 85.5  18.7 pg/ml at low dose, 414 
53 pg/ml at high dose, and 117.1  51.9 pg/ml at completion (p
0.05). A significant hemodynamic response was observed during
oth low- and high-dose AII infusion (Fig. 1). Systolic/diastolic
lood pressures were 117.0  2.2/76  2.4 mm Hg at baseline;
23.0  2.3/81.6  2.2 mm Hg at low dose (p  0.01); 138.0 
.6/91.5  2.9 mm Hg at high dose (p  0.01); and 111.6 
.3/73.9  2.3 mm Hg at completion, respectively (Fig. 1).
Atrial refractoriness did not show a significant acute change in
esponse to AII at any of the sites and cycle lengths tested (Fig. 2).
here was no significant increase in dispersion of ERP in response
o AII. Dispersion at 400 ms at baseline was 35.4  9.4 ms, at
ow-dose AII was 36.1  8.5 ms, and at high-dose AII was 32 
.9 ms. Conduction times as measured in both right and left atria
ere not significantly altered by AII (Fig. 2). Conduction delay
long the CT as determined by the number and width of double
otentials and fractionated signals was not significantly altered by
II. There was no significant change in AF inducibility or
uration during either low- or high-dose AII.
This study presents detailed prospective information on the
cute atrial electrophysiological effects of AII in humans. Noon in plasma levels (left panel) as well as systolic blood pressure (BP)
rt rate (HR).
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155JACC Vol. 45, No. 1, 2005 Correspondence
January 4, 2005:154–64ignificant direct effects on atrial electrophysiology were observed
n response to an infusion of AII sufficient to produce a seven-fold
ncrease in the plasma level of AII and a highly significant
emodynamic response. The AII level achieved was significantly
reater than that observed in heart failure (5).
The renin angiotensin system has been implicated previously in
cute atrial electrical remodeling. In the rapid atrial pacing model,
t has been shown that AII levels increase in the first 24 h and then
lateau for the duration of rapid atrial pacing (6). Nakashima et al.
2) demonstrated that dogs treated with either candesartan or
aptopril showed complete inhibition of electrical remodeling seen
n response to 3 h of rapid atrial pacing. They concluded that AII
ight be implicated in the mechanism of acute remodeling.
owever, Shinagawa et al (7) observed no effect of enalapril on
trial remodeling in dogs subjected to rapid atrial pacing for seven
ays.
Several previous animal studies have demonstrated that AII may
ave direct electrophysiologic effects via modification of ion
hannel function. However, these effects generally were seen at
oncentrations beyond physiologic levels.
The renin angiotensin system also has been implicated in
hronic atrial remodeling in animals (2,3,6,8) and humans (9).
eminal work by Li et al. (3) in dogs with heart failure found that
nalapril attenuated the effects of heart failure on atrial conduction,
brosis, and AF promotion. Clinical studies have suggested that
II antagonists or angiotensin-converting enzyme inhibitors may
e effective in reducing AF in patients with heart failure or after
ardioversion (10,11).
Angiotensin II infusion at doses sufficient to produce significant
emodynamic effects does not have any measurable effect on atrial
lectrophysiology in humans. It is therefore unlikely to be impli-
ated in the mechanism of acute electrical remodeling. However,
hese results do not exclude it from having an important role in
hronic fibrosis-related remodeling.
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MI  acute myocardial infarction; BMI  body mass index; CHF  chronic heart fail
holesterol.1. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the
incidence of atrial fibrillation in patients with left ventricular dysfunc-
tion: insight from the Studies Of Left Ventricular Dysfunction331–6. (SOLVD) trials. Circulation 2003;107:2926–31.x After Complicated Myocardial Infarctiono the Editor: Obesity is related to cardiovascular risk factors
nd is an independent risk factor for coronary artery disease
CAD) and premature death (1,2). However, the importance of
besity to mortality and morbidity in patients with established
AD is not well defined. The present analysis evaluated the
mportance of body mass index (BMI) to prognosis after compli-
ated acute myocardial infarction (AMI).
In post-hoc analysis, we examined the impact of baseline BMI
n all-cause death, cardiac death (death from AMI, chronic heart
ailure [CHF], other cardiac causes, and sudden cardiac death),
ancer death, and AMI and CHF hospitalization in 5,388 patients
ith complicated AMI who were included in the OPtimal Trial In
yocardial infarction with the Angiotensin II Antagonist Losar-
an (OPTIMAAL) (3). Prior to data analysis, patients were
ategorized into four BMI groups: underweight, 22.00; normal
eight, 22.00 to 24.99; overweight, 25.00 to 29.99; obese, 30.00
g/m2. Univariate and multivariate logistic regression analysis and
nalysis of variance were performed (StatView 5.0.1, SAS Insti-
ute, Cary, North Carolina). Multivariate analyses adjusted for 46
ariables comprising demographics, patient history, medication,
hysical examination, and biochemical analyses. Mean study drug
able 1. Baseline Characteristics by Baseline BMI Group
Baseline Characteristic
Underweight
n  485 (9%)
Mean SD M
ge (yrs) 70.3 10.70 6
ulse rate (beats/min) 75.6 14.17 7
ystolic blood pressure (mm Hg) 120.3 17.85 12
riglycerides (mmol/l) 1.60 0.66
DL (mmol/l) 1.24 0.34
DL (mmol/l) 3.42 1.03
emoglobin (g/l) 129.8 15.41 13
otassium (mmol/l) 4.17 0.49
ric acid (mol/l) 321.3 111.7 33
erum creatinine (mmol/l) 97.6 26.27 10
lucose (mmol/l) 7.09 2.80
n %
emale gender 209 43.1 38
urrent smoker 216 44.5 48
istory of CHF 37 7.6 10
istory of diabetes 48 9.9 17
istory of hypercholesterolemia 121 24.9 43
istory of AMI 92 19.0 25
n-hospital aspirin 457 94.2 135
n-hospital beta-blocker 354 73.0 116
n-hospital diuretic 315 64.9 91
n-hospital statin 176 36.3 64
n-hospital thrombolytic 253 52.2 74ose percent (MSDD%) was calculated as mean percentage of the
tudy drug target dose (captopril/losartan) during each patient’s
ollow-up. We denoted significance to be p  0.05.
Baseline BMI ranged from 13.2 to 49.4 kg/m2. Table 1 depicts
aseline characteristics. Median follow-up was 2.8 years (range 1 to
,471 days). Table 2 shows the main results of univariate and
ultivariate analyses. Additionally, BMI categories had similar ad-
usted risk of cancer death (n 83), CHF hospitalization (n 585),
nd number of CHF hospitalizations (n  916) and CHF hospital-
zation days (n 8,646). One-week mortality was comparable among
MI categories (1.8% to 2.5%). The BMI category was indepen-
ently (p  0.018) related to the number of AMIs (n  975)—
djusted relative frequency compared with normal-weight: under-
eight, 0.93; overweight, 0.78; obese, 0.82.
In univariate analysis, there was a significant association be-
ween BMI category and MSDD%: underweight, 68.55; normal
eight, 70.24; overweight, 74.13; obese, 76.91. In univariate
nalysis, a higher MSDD% was significantly protective of all end
oints (p 0.0001), except cancer death. However, the addition of
SDD% to the multivariate analyses did not attenuate the
ndependent associations shown in Table 2.
Baseline BMI Group
Normal
1421 (26%)
Overweight
n  2520 (47%)
Obese
n  962 (18%)
SD Mean SD Mean SD
10.02 66.6 9.55 65.5 9.19
14.49 75.3 13.94 75.3 14.06
16.09 123.0 16.72 126.5 17.42
0.76 1.97 0.93 2.18 1.10
0.32 1.15 0.29 1.12 0.28
1.03 3.38 1.12 3.32 1.23
14.29 135.0 13.87 136.0 14.54
0.44 4.16 0.46 4.14 0.45
101.9 345.6 93.6 362.7 96.8
24.51 100.4 20.95 99.4 22.68
2.90 7.56 3.15 7.98 3.16
% n % n %
27.3 605 24.0 342 35.6
34.3 796 31.6 303 31.5
7.2 121 4.8 74 7.7
12.6 448 17.8 255 26.5
30.5 836 33.2 374 38.9
18.2 444 17.6 179 18.6
95.5 2412 95.7 92.1 95.7
82.1 2098 83.3 796 82.7
64.6 1655 65.7 705 73.3
45.1 1242 49.3 501 52.1
52.6 1437 57.0 516 53.6n 
ean
8.9
4.6
0.7
1.72
1.19
3.33
2.0
4.16
0.4
0.1
7.19
n
8
7
2
9
4
9
7
6
8
1
7ure; HDL  high-density lipoprotein cholesterol; LDL  low-density lipoprotein
